Doheny Eye Institute Research Breakthrough: An Inherited Mutation Blinds Young Adult Males By Disturbing Mitochondrial Quantum Electron Tunneling
29 janv. 2024 12h05 HE
|
Doheny Eye Institute
PASADENA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, is pleased to announce the publication of important new findings...
L-carnitine Market to reach $312.8 Mn by 2032, Says Global Market Insights Inc.
15 janv. 2024 18h00 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Jan. 15, 2024 (GLOBE NEWSWIRE) -- The L-carnitine market valuation is projected to cross USD 312.8 million by 2032, as reported in a research study by Global Market...
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
26 avr. 2023 04h00 HE
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, April 26, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has...
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
19 avr. 2023 04h00 HE
|
NRG Therapeutics Limited
Vad Lazari Ph.D., appointed to the newly created position of VP of Biology, based in Stevenage, UKJoins from Charles River and brings two decades of drug discovery experience including at Pfizer and...
NRG Therapeutics Announces International Scientific Advisory Board
30 mars 2023 04h00 HE
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, March 30, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce the formation of...
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
22 févr. 2023 04h00 HE
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, Feb. 22, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been...
NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
09 févr. 2023 04h01 HE
|
NRG Therapeutics Limited
Gilles Ouvry Ph.D, appointed to newly created position of VP of Chemistry, based in Stevenage, UKJoins from Evotec, UK and brings 20 years of international medicinal chemistry experience including at...
Minovia Therapeutics appoints Maha Radhakrishnan, Chief Medical Officer at Biogen, as board member
05 janv. 2023 08h00 HE
|
Minovia Therapeutics
TIRAT HACARMEL, Israel, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics (Minovia), a clinical-stage company focused on developing novel Mitochondrial Augmentation Technology (MAT) to fight...
Minovia Therapeutics to Present at Biotech Showcase on Tuesday, January 10, 2023
03 janv. 2023 02h00 HE
|
Minovia Therapeutics
WOBURN, Mass. and HAIFA, Israel, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Minovia Therapeutics, a clinical-stage global biotechnology company, today announced that the Company will be presenting at the...
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
17 mars 2021 07h00 HE
|
Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...